Bone turnover markers: understanding their value in clinical trials and clinical practice

Area of Science:

• Biochemistry
• Orthopedics
• Endocrinology

Background:

• Bone mineral density (BMD) is the standard for fracture risk assessment.
• Bone turnover markers (BTMs) offer additional insights into bone health and treatment response.
• Assessing bone turnover is crucial for managing patients with low bone mass.

Purpose of the Study:

• To evaluate the role of BTMs in predicting fracture risk and monitoring osteoporosis treatment efficacy.
• To compare the predictive value of BTMs with BMD alone and in combination with BMD.
• To explore the potential clinical applications of BTMs beyond research settings.

Main Methods:

• Utilized BTMs in population-based studies and clinical trials.
• Compared fracture risk prediction using BMD alone versus BMD combined with BTMs.
• Assessed the rapid changes in bone turnover following antiresorptive therapy initiation.

Main Results:

• BTMs independently predict fracture risk, even surpassing BMD in some cases.
• Combining BTMs with BMD improves fracture risk estimation in postmenopausal women.
• Changes in bone turnover are detectable much faster than BMD changes after treatment.

Conclusions:

• BTMs are valuable in clinical trials for assessing osteoporosis treatment efficacy.
• Widespread clinical adoption for predicting individual fracture prevention is currently limited by marker variability.
• BTMs show potential for monitoring adherence and identifying appropriate patients for antiresorptive therapy, pending assay improvements.